R. Furie

602 total citations · 1 hit paper
11 papers, 442 citations indexed

About

R. Furie is a scholar working on Rheumatology, Pathology and Forensic Medicine and Nephrology. According to data from OpenAlex, R. Furie has authored 11 papers receiving a total of 442 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Rheumatology, 4 papers in Pathology and Forensic Medicine and 3 papers in Nephrology. Recurrent topics in R. Furie's work include Systemic Lupus Erythematosus Research (7 papers), Monoclonal and Polyclonal Antibodies Research (3 papers) and Renal Diseases and Glomerulopathies (3 papers). R. Furie is often cited by papers focused on Systemic Lupus Erythematosus Research (7 papers), Monoclonal and Polyclonal Antibodies Research (3 papers) and Renal Diseases and Glomerulopathies (3 papers). R. Furie collaborates with scholars based in United States, United Kingdom and Switzerland. R. Furie's co-authors include Helena Erlandsson Harris, Riikka Kokkola, Erik Sundberg, Kevin J. Tracey, Huan Yang, Nicholas Chiorazzi, A.‐K. Ulfgren, Luis Ulloa, Karin Palmblad and Jan Andersson and has published in prestigious journals such as Annals of the Rheumatic Diseases, Nature Reviews Rheumatology and Arthritis Care & Research.

In The Last Decade

R. Furie

9 papers receiving 433 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Advancements and challenges in CAR T cell therapy in autoimmune diseases

2024 85 citations Georg Schett, Fabian Müller et al. Nature Reviews Rheumatology profile →

Peers

R. Furie

IMMUN

CB

RHEUM

MB

ONCOL

Lingli Dong China

Hans Nienhuis Netherlands

Huaxi Xu China

Rena Tanikawa Japan

Bingxia Ming China

E. Schrama Netherlands

Yasuhiko Tomino Japan

Ing‐Marie Fyhr Sweden

Niamh Bermingham Ireland

María Soledad Fernández‐García Spain

Lingli Dong China

R. Furie

146 ×0.7

IMMUN

41 ×0.2

CB

66 ×0.5

RHEUM

109 ×1.2

MB

21 ×0.3

ONCOL

Citations per year, relative to R. Furie R. Furie (= 1×) peers Lingli Dong

Countries citing papers authored by R. Furie

Since Specialization

Citations

This map shows the geographic impact of R. Furie's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by R. Furie with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites R. Furie more than expected).

Fields of papers citing papers by R. Furie

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by R. Furie. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by R. Furie. The network helps show where R. Furie may publish in the future.

Co-authorship network of co-authors of R. Furie

This figure shows the co-authorship network connecting the top 25 collaborators of R. Furie. A scholar is included among the top collaborators of R. Furie based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with R. Furie. R. Furie is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

11 of 11 papers shown

1.

Schett, Georg, Fabian Müller, Jule Taubmann, et al.. (2024). Advancements and challenges in CAR T cell therapy in autoimmune diseases. Nature Reviews Rheumatology. 20(9). 531–544. 85 indexed citations breakdown →

2.

Furie, R., Jorge Alfonso Ross Terres, Edésio Martins, et al.. (2024). POS0529 OBINUTUZUMAB BENEFITS PATIENTS WITH ACTIVE LUPUS NEPHRITIS IRRESPECTIVE OF BASELINE PROTEINURIA SEVERITY: A POST HOC ANALYSIS OF THE PHASE II NOBILITY TRIAL. Annals of the Rheumatic Diseases. 83. 961–961.

3.

Furie, R., et al.. (2023). AB0518 EFFECT OF LITIFILIMAB ON TYPE I INTERFERON (IFN) BIOMARKERS IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) OR CUTANEOUS LUPUS ERYTHEMATOSUS (CLE): RESULT OF THE LILAC PHASE 2 STUDY. Annals of the Rheumatic Diseases. 82. 1453–1454.

4.

Morand, Eric F., R. Furie, Edward M Vital, et al.. (2022). POS0190 EFFICACY AND SAFETY OF BARICITINIB IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS: RESULTS FROM TWO RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, PHASE 3 STUDIES. Annals of the Rheumatic Diseases. 81. 327–328. 6 indexed citations

5.

Furie, R., et al.. (2021). POS0695 KZR-616, A SELECTIVE IMMUNOPROTEASOME INHIBITOR FOR THE TREATMENT OF SYSTEMIC LUPUS ERYTHEMATOSUS: RESULTS FROM THE COMPLETED DOSE ESCALATION PHASE 1B PORTION OF THE MISSION STUDY. Annals of the Rheumatic Diseases. 80. 595–596. 10 indexed citations

6.

Furie, R., Brad H. Rovin, Frédéric Houssiau, et al.. (2021). POS0689 A 6-MONTH OPEN-LABEL EXTENSION STUDY OF THE SAFETY AND EFFICACY OF INTRAVENOUS BELIMUMAB IN PATIENTS WITH LUPUS NEPHRITIS. Annals of the Rheumatic Diseases. 80. 591–592. 2 indexed citations

7.

Amoura, Zahir, Philippe Rémy, Laurent Chiche, et al.. (2020). OP0166 ALTERNATIVE RENAL RESPONSE DEFINITIONS IN A RANDOMIZED, CONTROLLED TRIAL OF OBINUTUZUMAB FOR PROLIFERATIVE LUPUS NEPHRITIS. Annals of the Rheumatic Diseases. 79. 104–104. 7 indexed citations

8.

Furie, R., Michelle Petri, Caroline Gordon, et al.. (2014). THU0023 Correlation of Laboratory and Clinical Parameters with British Isles Lupus Assessment Group Response in an Open-Label Extension Study of Epratuzumab in Systemic Lupus Erythematosus. Annals of the Rheumatic Diseases. 73. 184–184. 1 indexed citations

9.

Furie, R., Morton Scheinberg, G. Léon, et al.. (2013). OP0116 Effects of Blisibimod, a Subcutaneous Inhibitor of B Cell Activating Factor, in Patients with SLE. Annals of the Rheumatic Diseases. 72. A90–A91. 4 indexed citations

10.

Keystone, Edward, Gerd R Burmester, R. Furie, et al.. (2008). Improvement in patient‐reported outcomes in a rituximab trial in patients with severe rheumatoid arthritis refractory to anti–tumor necrosis factor therapy. Arthritis Care & Research. 59(6). 785–793. 86 indexed citations

11.

Kokkola, Riikka, Erik Sundberg, A.‐K. Ulfgren, et al.. (2002). High mobility group box chromosomal protein 1: A novel proinflammatory mediator in synovitis. Arthritis & Rheumatism. 46(10). 2598–2603. 241 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact